May 28th 2025
This serialization system represents a business imperative that yields significant competitive advantages.
The rebrand creates a platform that is expected enhance the way life sciences companies bring their therapies to market.
May 21st 2025
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.
May 19th 2025
The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day delivery.
May 14th 2025
Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.
AmerisourceBergen will build three new DCs; Cardinal tucks in Harvard Drug Corp.
Olive Branch, MS; Shakopee, MN; and Newburgh, NY are the designated ABC sites
A Conversation with Shabbir Dahod, TraceLink
Accenture finds an industry turnaround in 'future value'
Novo Nordisk is tagged as the only 'high performer'
US spending on drugs hit $373.9 billion in 2014, up 13.1%
Effect of the first full year of Obamacare was muted, although a record number of prescriptions were written
H. D. Smith reorganizes, expands upper management
Creation of a holding company streamlines future acquisitions; focus is on specialty drug services
A conversation with W. Scott Evangelista, Quintiles
Campbell Alliance updates, expands its commercial launch consulting services
More executional capabilities derive from affiliation with parent, inVentiv Health
Rite Aid to buy EnvisionRx, continuing a reshaping of US drug distribution
$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores
Independent physicians and their clinics remain a dominant channel for specialty distribution, says HDMA
Association's annual specialty-distribution study focuses trend in oncology, chronic diseases
Next agg-spend deadline looms with little buzz from industry
Reporting by pharma companies on spending on physicians is becoming a non-event
The biosimilars payoff in the US might be small and fleeting
Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US
ACOs raise the stakes for evidence-based medicine
Manufacturers will need to refine their interactions with healthcare providers and produce better outcomes research and adherence programs to compete
With acquisition of OptumHealth assets, Mapi Group bids to capture health economics consulting work globally
Mapi Group casts itself as a leading 'health research and commercialization' player
Walgreens-Alliance Boots tie-up is formally approved
So long WAG, hello to WBA as pharma manufacturers look at a consolidating buyer landscape
Hepatitis C therapies multiply and price concessions appear behind the scenes
Express Scripts touts a 'fundamental change' in drug pricing; others would call it negotiating a discount
Managing government pricing programs
When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
A conversation with Phil Hagerman, Diplomat Pharmacy
BioNJ industry survey sees biotech establishment growth but employment decline
A big jump in 2012-2013 venture funding will fuel growth; BMS' new facility
Omnicare Specialty expands its offices; scores another client
Company is part of limited distribution for a Lundbeck neurologic treatment
IMS Health's top 10 'harbingers of change' in pharmaceutical business
Payer trends dominate near-term outlook
AmerisourceBergen's ThinkLive manufacturer summit highlights an international push
Efforts to align drug wholesaling business with manufacturer services
Diplomat Pharmacy has a successful IPO, garnering $173 million
Largest independent specialty pharmacy rides specialty-pharma wave
ASD Healthcare's Cubixx system transmits its 400-billionth RFID scan
Vendor-managed system inventories and protects specialty pharmaceuticals in healthcare settings
A conversation with Homi Kapadia, Deloitte Life Sciences
A conversation with Seyed Mortazavi, IMS Health
Pharmaceutical Commerce sat down with Mr. Mortazavi recently; here's what he had to say.
Investor group calls on biotech manufacturers' boards to be more forthright on biosimilars
Absence of agreed-on FDA guidance keeps biosimilars off the US market even as their use grows abroad
PBM formulary exclusion lists continue to grow
Battlefield over drug pricing
Catalent goes public in a successful IPO
Blackstone Group-owned CDMO nets over $800 million
For pharma, it's getting harder and harder to follow the money
Outsourced contract-administration provider highlights growth in invoicing and financial stewardship burdens
Telerx to acquire C3i
Acquisition will add C3i's multilingual service-desk support to Telerx's call centers